Note: This story was updated March 29, 2022, to remove a reference to Phi Beta Sigma as the oldest…
Articles by Patricia Inácio, PhD
Sangamo Therapeutics is assuming all rights to SAR445136, an investigational gene-edited cell therapy co-developed with Sanofi and now in a Phase…
Imara has announced that it will change the main goal of its ongoing Phase 2b Ardent trial, which is…
Scientists Kenneth Ataga, MD, and Santosh Saraf, MD, have received a $3.2 million grant to continue investigating the potential of…
Health Canada has expanded its approval of Chiesi Global Rare Diseases’ iron-binding oral treatment Ferriprox (deferiprone) to patients who…
People with sickle cell disease (SCD) in Ghana — a country in sub-Saharan Africa, a region with the world’s…
Two years since its establishment, the Networking California for Sickle Cell Care initiative has seen increasing numbers of specialized…
The 10th Annual Sickle Cell Disease Therapeutics Conference, to be held virtually Sept. 15, will highlight the most recent medical…
FTX-6058, an investigational oral treatment being developed by Fulcrum Therapeutics for sickle cell disease (SCD) and beta-thalassemia, was found to…
As a stem cell transplant is the only curative treatment for sickle cell disease (SCD), a blood disorder…